Silvan Tuerkcan
Stock Analyst at Citizens
(4.30)
# 416
Out of 5,106 analysts
184
Total ratings
46.11%
Success rate
19.46%
Average return
Main Sectors:
Stocks Rated by Silvan Tuerkcan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRSP CRISPR Therapeutics AG | Reiterates: Market Outperform | $86 | $56.46 | +52.32% | 17 | Dec 23, 2025 | |
| TERN Terns Pharmaceuticals | Maintains: Market Outperform | $35 → $57 | $41.53 | +37.25% | 15 | Dec 11, 2025 | |
| NUVB Nuvation Bio | Maintains: Market Outperform | $8 → $10 | $9.34 | +7.07% | 5 | Nov 20, 2025 | |
| ENGN enGene Holdings | Maintains: Market Outperform | $18 → $21 | $9.22 | +127.77% | 5 | Nov 12, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Market Outperform | $29 → $21 | $9.42 | +122.93% | 14 | Nov 7, 2025 | |
| TSHA Taysha Gene Therapies | Maintains: Market Outperform | $6 → $8 | $5.71 | +40.11% | 14 | Nov 5, 2025 | |
| BNTC Benitec Biopharma | Maintains: Market Outperform | $20 → $22 | $12.93 | +70.15% | 14 | Nov 4, 2025 | |
| JSPR Jasper Therapeutics | Maintains: Market Outperform | $12 → $6 | $1.81 | +231.49% | 7 | Sep 22, 2025 | |
| PHR Phreesia | Maintains: Market Outperform | $30 → $34 | $16.78 | +102.62% | 1 | Sep 8, 2025 | |
| IDYA IDEAYA Biosciences | Maintains: Market Outperform | $41 → $45 | $35.41 | +27.08% | 2 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $50 | $46.61 | +7.27% | 23 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $15 | $5.90 | +154.24% | 3 | Jun 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $10 → $6 | $3.69 | +62.60% | 3 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $9 | $5.55 | +62.16% | 3 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $120 | $13.53 | +786.92% | 12 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $17 | $2.32 | +632.76% | 5 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $5.47 | - | 8 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $4 | $1.11 | +260.36% | 1 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $21 | $8.31 | +152.71% | 10 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.60 | - | 12 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $6 | $4.88 | +22.95% | 6 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $240 → $280 | $145.09 | +92.98% | 3 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $18 → $18 | $11.04 | +63.04% | 1 | Jan 26, 2023 |
CRISPR Therapeutics AG
Dec 23, 2025
Reiterates: Market Outperform
Price Target: $86
Current: $56.46
Upside: +52.32%
Terns Pharmaceuticals
Dec 11, 2025
Maintains: Market Outperform
Price Target: $35 → $57
Current: $41.53
Upside: +37.25%
Nuvation Bio
Nov 20, 2025
Maintains: Market Outperform
Price Target: $8 → $10
Current: $9.34
Upside: +7.07%
enGene Holdings
Nov 12, 2025
Maintains: Market Outperform
Price Target: $18 → $21
Current: $9.22
Upside: +127.77%
Intellia Therapeutics
Nov 7, 2025
Maintains: Market Outperform
Price Target: $29 → $21
Current: $9.42
Upside: +122.93%
Taysha Gene Therapies
Nov 5, 2025
Maintains: Market Outperform
Price Target: $6 → $8
Current: $5.71
Upside: +40.11%
Benitec Biopharma
Nov 4, 2025
Maintains: Market Outperform
Price Target: $20 → $22
Current: $12.93
Upside: +70.15%
Jasper Therapeutics
Sep 22, 2025
Maintains: Market Outperform
Price Target: $12 → $6
Current: $1.81
Upside: +231.49%
Phreesia
Sep 8, 2025
Maintains: Market Outperform
Price Target: $30 → $34
Current: $16.78
Upside: +102.62%
IDEAYA Biosciences
Sep 8, 2025
Maintains: Market Outperform
Price Target: $41 → $45
Current: $35.41
Upside: +27.08%
Jul 29, 2025
Reiterates: Market Outperform
Price Target: $50
Current: $46.61
Upside: +7.27%
Jun 6, 2025
Reiterates: Market Outperform
Price Target: $15
Current: $5.90
Upside: +154.24%
May 20, 2025
Maintains: Market Outperform
Price Target: $10 → $6
Current: $3.69
Upside: +62.60%
May 15, 2025
Reiterates: Market Outperform
Price Target: $9
Current: $5.55
Upside: +62.16%
May 9, 2025
Downgrades: Market Perform
Price Target: $120
Current: $13.53
Upside: +786.92%
Mar 26, 2025
Reiterates: Market Outperform
Price Target: $17
Current: $2.32
Upside: +632.76%
Mar 14, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $5.47
Upside: -
Jan 8, 2025
Initiates: Market Outperform
Price Target: $4
Current: $1.11
Upside: +260.36%
Dec 12, 2024
Reiterates: Market Outperform
Price Target: $21
Current: $8.31
Upside: +152.71%
Nov 7, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $1.60
Upside: -
May 31, 2024
Reiterates: Market Outperform
Price Target: $6
Current: $4.88
Upside: +22.95%
Mar 5, 2024
Maintains: Buy
Price Target: $240 → $280
Current: $145.09
Upside: +92.98%
Jan 26, 2023
Maintains: Market Outperform
Price Target: $18 → $18
Current: $11.04
Upside: +63.04%